Selective alpha 2-adrenoceptor blockade does not enhance glucose-evoked insulin release

Area of Science:

• Pharmacology
• Endocrinology
• Neuroscience

Background:

• Alpha 2-adrenoceptors play a role in regulating pancreatic insulin secretion and glucose metabolism.
• Selective alpha 2-adrenoceptor agonists, like UK 14304, have been shown to inhibit insulin release and increase blood glucose levels.

Purpose of the Study:

• To investigate the effects of the selective alpha 2-adrenoceptor antagonist, idazoxan, on plasma insulin and glucose responses to a glucose stimulus in conscious rats.
• To determine if alpha 2-adrenoceptor blockade by idazoxan influences pancreatic insulin secretion and glycemic control.

Main Methods:

• Administration of a selective alpha 2-adrenoceptor agonist (UK 14304) and antagonist (idazoxan) to conscious, euglycaemic rats.
• Measurement of plasma immunoreactive insulin and glucose levels following an intra-arterial glucose load.
• Assessment of the effects of idazoxan alone and in combination with UK 14304 on these responses.

Main Results:

• The alpha 2-adrenoceptor agonist UK 14304 reduced insulin response and potentiated hyperglycemia, confirming its known effects.
• Idazoxan completely abolished the effects of UK 14304, demonstrating effective alpha 2-adrenoceptor antagonism.
• Idazoxan administered alone did not significantly alter plasma glucose or insulin levels in response to glucose challenge.

Conclusions:

• Selective alpha 2-adrenoceptor blockade with idazoxan does not potentiate glucose-evoked insulin secretion.
• The study confirms the involvement of alpha 2-adrenoceptors in modulating insulin secretion and glycemia.
• Idazoxan effectively antagonizes alpha 2-adrenoceptor-mediated effects at the dose studied.